A new study published in Alzheimer’s & Dementia highlights a significant step forward in diagnosing Dementia with Lewy Bodies (DLB) in its early stages.
DLB is the second most common neurodegenerative dementia after Alzheimer’s Disease but is often misdiagnosed.
This misdiagnosis can delay the right treatments, leaving affected individuals without care tailored to their specific needs.
Led by Dr. Ece Bayram, an assistant professor of neurology at the University of Colorado Anschutz Medical Campus, the study sought to address this challenge.
“While there are criteria to identify DLB in research settings, we aimed to develop guidelines that clinicians can use in everyday practice,” Dr. Bayram explained. By analyzing multiple research studies, the team established a cognitive profile that distinguishes DLB from Alzheimer’s in its early, pre-dementia stage.
The study’s meta-analysis revealed distinct differences in cognitive abilities between people with DLB and those with Alzheimer’s before dementia becomes severe. People with DLB showed greater difficulties with attention, processing speed, and executive functions (skills related to planning and decision-making).
However, their immediate memory and recall abilities were better preserved compared to individuals with Alzheimer’s. These differences provide valuable clues for identifying DLB earlier in the disease process.
One of the study’s most impactful findings is its focus on practical, accessible tools for diagnosis. Instead of relying on expensive imaging techniques or invasive biomarker tests, the research highlights the potential of cognitive assessments.
Dr. Bayram noted, “It’s easier and more affordable to train healthcare providers to perform cognitive assessments than to use specialized tests. This means more people, even those without access to advanced medical facilities, can benefit from early and accurate diagnoses.”
Early diagnosis of DLB is critical for many reasons. It helps individuals and their families plan for the future, ensuring they receive the right treatments and support. Proper identification of DLB can also prevent the use of medications that might worsen the condition.
For example, certain drugs often prescribed for psychosis, like haloperidol, can be harmful to people with DLB. Tailoring treatments based on an accurate diagnosis can significantly improve the quality of life for both patients and caregivers.
Dr. Bayram emphasized the broader impact of this work. “We’re seeing more treatment trials focused on slowing or modifying diseases like Alzheimer’s and DLB.
By diagnosing DLB earlier, we can prevent or delay the onset of dementia, rather than waiting to address it after severe brain damage has occurred. These clinical assessments open the door for equitable care, even for those without access to specialty centers.”
In conclusion, this study represents a significant step forward in dementia research and care. By establishing a clear cognitive profile for DLB and focusing on accessible diagnostic tools, it paves the way for earlier interventions, better treatment outcomes, and improved quality of life for individuals and families affected by this challenging condition.
It also reinforces the importance of early detection, not just for improving current care but for advancing future treatments aimed at disease prevention.
If you care about Alzheimer’s disease, please read studies about the protective power of dietary antioxidants against Alzheimer’s, and eating habits linked to higher Alzheimer’s risk.
For more information about brain health, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
The research findings can be found in Alzheimer’s & Dementia.
Copyright © 2025 Knowridge Science Report. All rights reserved.